Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Fig. 3

Kaplan-Meier curves of overall survival in a the unadjusted analysis (number of patients at risk are shown), b sIPTW-adjusted analysis (number of patients at risk are shown), and c after PSM. LET, letrozole; NE, not estimable; NR, not reached; OS, overall survival; PAL, palbociclib; PSM, propensity score matching; sIPTW, stabilized inverse probability of treatment weighting

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us